| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Serine/threonine-protein kinase 4 |
|---|
| Ligand | BDBM50359359 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_793923 (CHEMBL1931515) |
|---|
| IC50 | >30000±n/a nM |
|---|
| Citation |  Moffett, K; Konteatis, Z; Nguyen, D; Shetty, R; Ludington, J; Fujimoto, T; Lee, KJ; Chai, X; Namboodiri, H; Karpusas, M; Dorsey, B; Guarnieri, F; Bukhtiyarova, M; Springman, E; Michelotti, E Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). Bioorg Med Chem Lett21:7155-65 (2011) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Serine/threonine-protein kinase 4 |
|---|
| Name: | Serine/threonine-protein kinase 4 |
|---|
| Synonyms: | KRS2 | MST1 | STK4 | STK4_HUMAN | Serine/threonine-protein kinase 3/4 | Serine/threonine-protein kinase 4 (STK4) | Serine/threonine-protein kinase MST1 |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 55611.40 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q13043 |
|---|
| Residue: | 487 |
|---|
| Sequence: | METVQLRNPPRRQLKKLDEDSLTKQPEEVFDVLEKLGEGSYGSVYKAIHKETGQIVAIKQ
VPVESDLQEIIKEISIMQQCDSPHVVKYYGSYFKNTDLWIVMEYCGAGSVSDIIRLRNKT
LTEDEIATILQSTLKGLEYLHFMRKIHRDIKAGNILLNTEGHAKLADFGVAGQLTDTMAK
RNTVIGTPFWMAPEVIQEIGYNCVADIWSLGITAIEMAEGKPPYADIHPMRAIFMIPTNP
PPTFRKPELWSDNFTDFVKQCLVKSPEQRATATQLLQHPFVRSAKGVSILRDLINEAMDV
KLKRQESQQREVDQDDEENSEEDEMDSGTMVRAVGDEMGTVRVASTMTDGANTMIEHDDT
LPSQLGTMVINAEDEEEEGTMKRRDETMQPAKPSFLEYFEQKEKENQINSFGKSVPGPLK
NSSDWKIPQDGDYEFLKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQSKRQPILDAIEAK
KRRQQNF
|
|
|
|---|
| BDBM50359359 |
|---|
| n/a |
|---|
| Name | BDBM50359359 |
|---|
| Synonyms: | CHEMBL1929238 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C25H33Cl2N5O3S |
|---|
| Mol. Mass. | 554.532 |
|---|
| SMILES | CN(C)CCN1CCN(CCC1=O)C(=O)c1cc(sc1NC(=O)Nc1cccc(Cl)c1Cl)C(C)(C)C |
|---|
| Structure | 
|
|---|
Search and Browse
